BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30068243)

  • 41. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
    Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Deep sequencing reveals lack of a clonal relationship between a metachronous classical hodgkin and diffuse large B-cell lymphoma.
    Siddiqi IN; Ailawadhi S; Huang Q; Shibata RK; Kang H; Shibata D
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):e87-93. PubMed ID: 24548610
    [No Abstract]   [Full Text] [Related]  

  • 43. Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA.
    Weerts MJA; Timmermans EC; van de Stolpe A; Vossen RHAM; Anvar SY; Foekens JA; Sleijfer S; Martens JWM
    Neoplasia; 2018 Jul; 20(7):687-696. PubMed ID: 29842994
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.
    Hahn AW; Gill DM; Maughan B; Agarwal A; Arjyal L; Gupta S; Streeter J; Bailey E; Pal SK; Agarwal N
    Oncotarget; 2017 May; 8(20):33614-33620. PubMed ID: 28431395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma.
    Roschewski M; Staudt LM; Wilson WH
    Blood; 2016 Jun; 127(25):3127-32. PubMed ID: 27081097
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.
    Alcaide M; Yu S; Bushell K; Fornika D; Nielsen JS; Nelson BH; Mann KK; Assouline S; Johnson NA; Morin RD
    Clin Chem; 2016 Sep; 62(9):1238-47. PubMed ID: 27440511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
    Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
    BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.
    Chen KZ; Lou F; Yang F; Zhang JB; Ye H; Chen W; Guan T; Zhao MY; Su XX; Shi R; Jones L; Huang XF; Chen SY; Wang J
    Sci Rep; 2016 Aug; 6():31985. PubMed ID: 27555497
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Circulating Plasma Tumor DNA.
    Parsons HA; Beaver JA; Park BH
    Adv Exp Med Biol; 2016; 882():259-76. PubMed ID: 26987539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical applications of circulating tumor DNA in Hodgkin lymphoma.
    Heger JM; Ferdinandus J; Mattlener J; Borchmann S
    Semin Hematol; 2023 Jul; 60(3):157-163. PubMed ID: 37422345
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
    Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification and Use of Personalized Genomic Markers for Monitoring Circulating Tumor DNA.
    Chen Y; George AM; Olsson E; Saal LH
    Methods Mol Biol; 2018; 1768():303-322. PubMed ID: 29717450
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Preliminary analysis of mutations in exon 5 of IkappaBalpha gene in Hodgkin lymphoma].
    Liu XJ; Yang WT; Zhou XY; Yan Q; Shi DR
    Zhonghua Bing Li Xue Za Zhi; 2005 Jun; 34(6):341-4. PubMed ID: 16185501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA.
    Pécuchet N; Rozenholc Y; Zonta E; Pietrasz D; Didelot A; Combe P; Gibault L; Bachet JB; Taly V; Fabre E; Blons H; Laurent-Puig P
    Clin Chem; 2016 Nov; 62(11):1492-1503. PubMed ID: 27624137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing.
    Amant F; Verheecke M; Wlodarska I; Dehaspe L; Brady P; Brison N; Van Den Bogaert K; Dierickx D; Vandecaveye V; Tousseyn T; Moerman P; Vanderstichele A; Vergote I; Neven P; Berteloot P; Putseys K; Danneels L; Vandenberghe P; Legius E; Vermeesch JR
    JAMA Oncol; 2015 Sep; 1(6):814-9. PubMed ID: 26355862
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High-Throughput and Sensitive Quantification of Circulating Tumor DNA by Microfluidic-Based Multiplex PCR and Next-Generation Sequencing.
    Guan Y; Mayba O; Sandmann T; Lu S; Choi Y; Darbonne WC; Leveque V; Ryner L; Humke E; Tam NWR; Sujathasarma S; Cheung A; Bourgon R; Lackner MR; Wang Y
    J Mol Diagn; 2017 Nov; 19(6):921-932. PubMed ID: 28867605
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-time detection of BRAF V600E mutation from archival hairy cell leukemia FFPE tissue by nanopore sequencing.
    Vacca D; Cancila V; Gulino A; Lo Bosco G; Belmonte B; Di Napoli A; Florena AM; Tripodo C; Arancio W
    Mol Biol Rep; 2018 Feb; 45(1):1-7. PubMed ID: 29238890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.